{"url_path":"/sec/zbio/8-k/2026-05-13/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059700-index.html","accession_number":"0001104659-26-059700","cik":"0001953926","ticker":"ZBIO","issuer_name":"Zenas BioPharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059700-index.html","primary_entity_key":"0001953926","primary_entity_name":"Zenas BioPharma, Inc."},"word_count":318,"has_tables":true,"body_markdown":"false\n0001953926\n\n0001953926\n\n2026-05-11\n2026-05-11\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n** **\n\n** **\n\n**FORM 8-K**\n\n** **\n\n** **\n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d)\nof the Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nMay 11, 2026**\n\n** **\n\n** **\n\n**ZENAS BIOPHARMA, INC.**\n\n**(Exact name of registrant as specified in its charter)**\n\n \n\n \n\n**Delaware**\n \n**001-42270**\n \n**93-2749244**\n\n**(State or other jurisdiction\nof incorporation)**\n \n**(Commission\nFile Number)**\n \n**(IRS Employer\nIdentification No.)**\n\n \n\n **852 Winter Street, Suite 250** **Waltham, MA**\n **02451**\n\n**(Address of principal executive offices)**\n**(Zip Code)**\n\n \n\n**(Registrant’s telephone number, including area code): (857) 271-2954**\n\n \n\n**Not Applicable**\n\n**(Former name or former address, if changed since\nlast report)**\n\n** **\n\n** **\n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) \n\n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) \n\n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n** **\n**Trading\nSymbol(s)**\n** **\n**Name\nof each exchange\non which registered**\n\n**Common Stock, par value $0.0001 per share**\n \n**ZBIO**\n \n**The Nasdaq Global Select Market**\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company x\n\n \n\nIf an emerging growth company, indicate\nby check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial\naccounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}